Suppr超能文献

[口服酮洛芬(优洛芬)与胃黏膜保护剂(磷酸铝,磷酸铝凝胶)联合使用时的生物利用度]

[The bioavailability of ketoprofen (Profenid) administered orally in combination with a gastric protector (aluminum phosphate, Phosphalugel)].

作者信息

Tamisier J N, Brazier J L, Ambert D, Bannier A

出版信息

Sem Hop. 1983 Dec 12;59(46):3214-7.

PMID:6318344
Abstract

Bioavailability of ketoprofen associated with aluminum phosphate was studied. Subjects were studied after an initial dose given without gastric protection, after ingestion of a single dose given with aluminum phosphate and, lastly, after four days of continuous treatment with this product. Results of plasma peak level and its time of occurrence, area under the curve, half-life and elimination constant establish that bioavailability of ketoprofen is not changed by association with aluminum phosphate. It is therefore unnecessary to modify dosages in such combination treatment. Lastly, there is no change in ketoprofen absorption liable to alter its efficacy.

摘要

研究了酮洛芬与磷酸铝联用的生物利用度。对受试者先给予初始剂量且无胃保护措施,接着给予单剂量酮洛芬与磷酸铝联用,最后给予该产品连续治疗四天后进行研究。血浆峰浓度及其出现时间、曲线下面积、半衰期和消除常数的结果表明,酮洛芬与磷酸铝联用不会改变其生物利用度。因此,在这种联合治疗中无需调整剂量。最后,酮洛芬的吸收没有变化,不会影响其疗效。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验